Investor Alert: ImmunityBio Securities Class Action Deadline on May 26, 2026

viernes, 27 de marzo de 2026, 5:04 pm ET1 min de lectura
IBRX--

Faruqi & Faruqi, LLP is investigating claims against ImmunityBio, Inc. (IBRX) for allegedly making false and misleading statements about Anktiva's capabilities. The lawsuit alleges that defendants violated federal securities laws, resulting in damages to investors. The court-appointed lead plaintiff must be chosen by May 26, 2026. Those with information regarding ImmunityBio's conduct are encouraged to contact the firm.

Investor Alert: ImmunityBio Securities Class Action Deadline on May 26, 2026

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios